Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb has introduced its new INFUSE for Astigmatism daily disposable contact lenses in the U.S. These lenses, designed with ProBalance Technology™ and OpticAlign® design, offer clear, stable vision and all-day comfort. The lenses address common issues for astigmatic patients, including dryness and blurred vision exacerbated by digital device use. The lenses feature kalifilcon A material that provides high moisture (55%) and breathability (107 Dk/t). They will be available to eye care professionals starting July 2024.

INFUSE for Astigmatism includes osmoprotectants, electrolytes, and moisturizers for a 16-hour wearing experience. A study showed 97% of these lenses had less than three degrees of rotation with blink. They also provide clear vision across the entire power range and reduce spherical aberration, halos, and glare. Additionally, Bausch + Lomb offers a recycling program for used contact lens materials.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Blink NutriTears, a new clinically proven over-the-counter supplement for dry eyes in the U.S. This product targets the root causes of dry eyes and promotes healthy tear production, providing relief within two to four weeks. The supplement contains lutein, zeaxanthin, curcumin, and vitamin D, shown to improve ocular symptoms and tear film homeostasis. Clinical studies indicate NutriTears can keep tears on the eyes 33% longer, offering significant symptom relief. It will be available in the eye care aisle and online at major retailers by the end of July.

Bausch + Lomb, a global eye health company, announced the results of its 2024 annual shareholder meeting held on May 29, 2024. All 10 nominated directors were elected. Key votes included Nathalie Bernier, Gary Hu, Brett Icahn, Sarah B. Kavanagh, Karen L. Ling, John A. Paulson, Russel C. Robertson, Thomas W. Ross Sr., Brenton L. Saunders, and Andrew C. von Eschenbach.

Shareholders approved executive compensation in a non-binding advisory vote and an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares authorized for issuance. PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting. The final vote results will be filed with the SEC on Form 8-K and will be available on the company's SEDAR+ profile and website.

Bausch + Lomb announced the presentation of new scientific data at the American Optometric Association's Optometry’s Meeting. Scheduled events include 12 ePosters and 3 live presentations, highlighting products like MIEBO, Blink NutriTears, and INFUSE. Key presentations will cover clinical data on Blink Triple Care Lubricating Eye Drops and Biotrue Hydration Plus Multi-Purpose Solution. The company will also host nine educational events. MIEBO and XIIDRA's benefits for dry eye disease and other eye health products will be discussed.

Bausch + Lomb (NYSE/TSX: BLCO) has received Health Canada approval for its new enVista® Envy™ intraocular lens (IOL), marking the first global regulatory approval of this product. The enVista Envy IOL offers a full visual range with high tolerance to dysphotopsia. Clinical trials in Canada showed excellent long-term outcomes, with 93% of patients reporting minimal visual disturbances and 94% experiencing little to no difficulty viewing close objects while achieving excellent distance vision without glasses. The lens features ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision in varying lighting conditions and reducing light scattering. Commercial availability in Canada is set for mid-June, with plans for additional regulatory approvals in the U.S. and Europe.

Bausch + Lomb (NYSE/TSX: BLCO) reported first-quarter 2024 results, with revenue reaching $1.099 billion, a GAAP net loss of $167 million, and an adjusted EBITDA of $180 million. The revenue grew by 18% as reported and 20% on a constant currency basis compared to the first quarter of 2023. The company experienced broad-based growth across all business segments and key franchises, with strong performance in Vision Care, Surgical, and Pharmaceuticals segments. The positive financial results were driven by growth in Daily SiHy lenses, LUMIFY, and eye vitamins, along with successful launches of MIEBO and XIIDRA. Bausch + Lomb also raised its full-year 2024 constant currency revenue growth guidance.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Summary: Bausch + Lomb (NYSE/TSX: BLCO) has revealed the presentation of 21 scientific posters at the Association for Research in Vision and Ophthalmology Annual Meeting. The posters showcase evaluations of consumer, pharmaceutical, surgical, and vision care products, as well as pipeline programs. Notably, a new dry eye nutritional supplement, Blink™ NutriTears®, stands out among the offerings. The company's commitment to advancing eye care through research and innovation is evident in this comprehensive display of data.

Bausch + Lomb announced statistically significant results from a clinical study on a novel daily nutritional supplement for dry eyes. The supplement, Blink NutriTears, showed improvements in tear production, ocular symptoms, tear-film break-up time, osmolarity, and ocular surface health. The study included 155 adult participants and met all primary and secondary endpoints, with no serious adverse events reported. The supplement is expected to be launched in the U.S. in the third quarter of 2024.

Bausch + Lomb, a global eye health company, reports collecting over 84 million units of used contact lenses, eye care, and lens care materials through recycling programs in the U.S. The company aims to reduce waste and promote environmental responsibility, repurposing collected materials into post-consumer products. Bausch + Lomb's sustainable business practices align with its mission of helping people see better to live better.